Blood disorder specialist Fulcrum Therapeutics has agreed to what amounts to a reverse merger with Slate Medicines, a privately held biotech focused on next generation therapies for migraine. The ...

Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, most notably a billion dollar partnership with Indianapolis-based Eli Lilly. "Biology is on the verge of its ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva-based ...

A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for hereditary haemorrhagic telangiectasia (HHT), the second most common inherited ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.

AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist drug with potential in ...

ChatGPT has already made waves and has been deployed to write codes, new poems, songs, recipes, and whatnot. Language models that use transformer-based architectures, such as GPT (Generative ...

Servier has advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome (FXS) from UK biotech Kaerus Bioscience. The ...

Novartis has added a T-cell engager (TCE) developed by China's Abogen Biosciences for autoimmune disorders in a deal that ...

Pharmaceutical launch plans are often thoroughly researched, carefully costed, and internally aligned. The problem is that ...

The UK is putting £80 million ($105 million) in funding behind nine technologies that it hopes will be able to diagnose ...